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Limited data are available examining the role of hypofractionated radiation schedules in the management
of women requiring regional nodal irradiation (RNI). The purpose of this review is to examine the avail-
able literature for the efﬁcacy (where available) and toxicity of hypofractionated radiation schedules in
breast cancer with RNI limited to the axilla and supraclavicular regions. Multiple randomized and pro-
spective studies have documented the safety and efﬁcacy of hypofractionated schedules delivering whole
breast irradiation (WBI) alone. Subsets from these randomized trials and smaller prospective/single-insti-
tution studies have documented the feasibility of hypofractionated RNI but the limited numbers prevent
deﬁnitive conclusions and limited efﬁcacy data are available. With regard to possible toxicity affecting
organs at risk with RNI, key structures include the breast, skin, heart, lungs, axilla (lymphedema), and
brachial plexus. Based on data from several randomized trials, hypofractionated radiation is not associ-
ated with signiﬁcant changes in breast toxicity/cosmesis or cardiac toxicity; the addition of hypofraction-
ated RNI would not be expected to change the rates of breast or cardiac toxicity. While RNI has been
shown to increase rates of pulmonary toxicity, hypofractionated RNI has not been associated with more
frequent pulmonary complications than standard RNI. Moving forward, future studies will have to eval-
uate for increased lung toxicity. With regard to lymphedema, data from randomized hypofractionated
WBI trials failed to demonstrate an increase in lymphedema and smaller studies utilizing hypofraction-
ated RNI have failed to as well. Data from head and neck cancer as well as hypofractionated breast radi-
ation with RNI have failed to demonstrate an increase in brachial plexopathy with the exception of older
trials that used much larger dose per fraction (>4 Gy/fraction) schedules. At this time, published data sup-
port the feasibility of hypofractionated RNI and the need for a prospective randomized trial addressing
clinical outcomes and toxicity of hypofractionated RNI compared with standard fractionation RNI.
 2014 The Authors. Published by Elsevier Ireland Ltd. Radiotherapy and Oncology 110 (2014) 39–44 This
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3.0/).Breast cancer represents the most common non-cutaneous
malignancy inwomen,with over 300,000 new cases diagnosed each
year in the United States [1].While there has been a reduction in the
incidence of locally advanced malignancies secondary to increased
mammographic screening and awareness, the utilization of regional
nodal irradiation (RNI) has increased recently in some countries in
response to data suggesting a beneﬁt for those with limited nodal
involvement (1–3 nodes positive) [2,3], a cohort where data sup-
porting the use of RNI were previously limited to patients receivingpost-mastectomy radiation [4], aswell as recent data supporting the
useofRNI inplaceof axillary lymphnodedissection forpatientswith
a positive sentinel lymph node [5]. Radiation treatment that incor-
porates RNI is typically prescribed over 5–6½weeks utilizing stan-
dard fractionation of 1.8–2 Gy per day. Shorter courses of radiation
are more cost-effective and open up the capacity of treatment facil-
ities and reduce patient treatment duration [6].
Over thepastdecade, in anattempt todecreasehealthcare spend-
ing and improve patient satisfaction, there has been increased utili-
zation of hypofractionated radiation therapy for patients
undergoing breast conserving treatment who require treatment to
the breast only. This is based in part on new radiobiological data
which have shown the radiosensitivity of breast cancer is not as
40 Hypofx Breast RT Reviewdependent on dose per fraction aswas previously thought [7]. Strat-
egies, including accelerated partial breast irradiation and hypofrac-
tionated whole breast irradiation (WBI), have been utilized with
mature data demonstrating comparable outcomes to standard frac-
tionated therapy. Some of the strongest data come fromCanada and
theUnitedKingdomwhere Phase III trials havedemonstratednodif-
ference in local control with hypofractionated WBI with long term
follow up [7,8].
One concern regarding hypofractionated schedules is the poten-
tial for increased acute and late long term toxicities based on
commonly used radiobiological models and data from other
treatment sites [9]. In regard to breast cancer patients, concerns
regarding late toxicity after hypofractionated therapy to the heart,
lungs, axilla (lymphedema), and brachial plexus along with skin
and breast cosmesis exist and limited published data in the post-
mastectomy and RNI settings are available. Therefore, this review
is to evaluate the potential for hypofractionated RNI in intact and
post mastectomy breast radiation based on a review of published
literature.Materials/methods
This review was conducted in line with the Preferred Reporting
Items for Systematic Reviews and Meta-Analyses (PRISMA) guide-
lines; however, a systematic review was not performed [10]. No
ofﬁcial review protocol was created for this review. Eligibility
criteria for this review included published studies in English, that
addressed hypofractionated radiation therapy in breast cancer
(excluding accelerated partial breast irradiation), or hypofraction-
ation with effect on target organs of concern. Required information
included a reviewable abstract, number of patients, length of fol-
low-up, radiation therapy details (total dose, fraction size and
treatment ﬁeld), and clinical outcomes (recurrence or toxicity). A
twenty year interval of publication was chosen in order to focus
on more recent literature which included modern surgical and
radiation therapy modalities. Sources of information for the review
included articles known to the authors, found via Medline/Pub-
Med, and those found in references from the major articles identi-
ﬁed. The PubMed search was conducted by two of the authors (CSTable 1
Hypofractionated RNI studies.
Study Type Year Patients Fract
Marsden [12] Randomized,
prospective
1986–1998 1,410 (14%
chemo, 20% RNI)
42.9/
39/13
25 (A
5 we
START A [7] Randomized,
prospective
1998–2002 2,236 (36%
chemo, 15%
PMRT, 14% RNI)
41.6/
39/13
25
START B [7] Randomized,
prospective
1999–2001 2,215 (22%
chemo, 8% PMRT,
7% RNI)
40/15
25
UZ Brussels [15] Randomized,
prospective
2007–2011 70 (33% RNI) 50/25
15
Greece [32] Prospective 2003–2010 112 (all PMRT, 73
RNI)
35/10
Thailand [33] Retrospective 2004–2006 215 (all PMRT; 67
conventional, 148
Hypofractionated)
50/25
42.4–
47.7.and SB) to identify publications with the following MeSH headings:
(1) accelerated, breast, radiation, and hypofractionated, (2)
hypofractionation, heart, lungs, brachial plexus, breast, radiation,
regional irradiation, and lymph nodes. When multiple updates
from a single study were available, the most recent data were uti-
lized unless results presented were unique to each publication. All
searches were completed by July 28, 2013.
Basedon the initial searches, a total of 148articleswere identiﬁed
including 12 articles that were known to the authors while 136 arti-
cles were acquired from the literature search; after duplicates were
removed, each of the eligible studies were screened independently
by two authors (SB and CS) with 33 excluded. Of the remaining
115 studies, full-text articles were assessed for eligibility with data
fromselected studies extracted including the typeof study (prospec-
tive v. retrospective), institution, number of patients, follow-up, use
of radiation therapy, and outcomes. Studies were excluded due to
small numbers of patients (<20), lack of clear radiation receipt, or
outcomes presented that were not within the scope of the review.
Due to the differences across studies, datawere unable to be pooled.
Forwholebreast irradiationonlypublications,we includedonlypro-
spective studies due to the large number of randomized and pro-
spective studies available. When evaluating post-mastectomy and
regional nodal hypofractionated studies, all studies were included
due to a paucity of data. A total of 25 studies were included in this
portion of the reviewwith ﬁve studies identiﬁed that included hyp-
ofractionated RNI (Table 1). With regard to the review of organs at
riskwithhypofractionated schedules a total of 40 studieswere iden-
tiﬁed including some previously identiﬁed in the search for hypo-
fractionated breast radiation.Results
Hypofractionated whole breast irradiation
Supplementary Materials Table presents a summary of random-
ized and prospective studies examining the role of hypofractionat-
ed whole breast irradiation [7,8,11–29]. At this time, there exist
multiple randomized trials that examined the long-term rates of
local control after breast conserving surgery and hypofractionated
versus standard whole-breast radiation therapy for early stageionation Follow-Up (mo) Outcomes
13 v.
v. 50/
ll in
eks)
115 No data regarding RNI subset of patients
13 v.
v. 50/
61 No difference in chest wall appearance, chest
pain/swelling, shoulder/arm function, and
lymphedema compared with standard
fractionation PMRT
v. 50/ 72 No difference in chest wall appearance, chest
pain/swelling, shoulder/arm function, and
lymphedema compared with standard
fractionation PMRT
v. 42/ 28 Reduced skin changes and lung function with
hypofractionation at 2 years; no difference in
ﬁbrosis, lymphedema, or cardiac function.
44 97% local control; no cases of pneumonitis.
Acute toxicity- 23% Grade 2 + dermatitis in
boost, 13% beyond ﬁeld, No Grade 2 + chest pain,
pneumonitis, edema, or erythema. Late toxicity-
Grade 2 + edema 4.4%, Grade 2 + ﬁbrosis, 7.1%,
Grade 2 + chest wall pain 1.8%, No Grade
2 + plexopathy 4% CT changes in lung
v.
2.65
39 No difference in loco-regional control; no
difference in chest wall appearance, ﬁbrosis,
appearance, plexopathy, lymphedema, cardiac,
pulmonary, or rib fractures
S.N. Badiyan et al. / Radiotherapy and Oncology 110 (2014) 39–44 41invasive breast cancer. The earliest study came from the Royal
Marsden Hospital, Sutton and Gloucestershire Oncology Centre
where over 1400 women were randomized to one of three arms
following BCS: 50 Gy in 25 fractions, 39 Gy in 13 fractions, or
42.9 Gy in 13 fractions with all schedules delivered over 5 weeks.
At 10-years, local recurrence rates were 12.1%, 14.8% and 9.6% for
women receiving standard fractionation, 39 Gy in 13 fractions,
and 42.9 Gy in 13 fractions, respectively with a signiﬁcant increase
in local recurrence for the 39 Gy cohort compared with the 42.9 Gy
cohort [30]. Following this study were the United Kingdom Stan-
dardization of Breast Radiotherapy (START) A and B trials which
randomized women to alternative hypofractionated schedules
over differing treatment durations. START A was a three arm trial
randomizing women to 50 Gy in 25 fractions, 41.6 Gy in 13
fractions, or 39 Gy in 13 fractions all delivered over 5 weeks. At a
median follow-up of 9.3 years no difference in local control was
noted between arms with a 10 year follow-up showing reduced
complications in the 39 Gy arm compared with the standard frac-
tionation arm [7]. START B compared 50 Gy in 25 fractions with
40 Gy in 15 fractions delivered in 5 and 3 weeks respectively. At
a median follow-up of 9.9 years no difference in local recurrence
was noted with improved toxicity and appearance outcomes noted
in the 40 Gy arm [7]. The Ontario Oncology Group randomized
1,234 women with early stage breast cancer to hypofractionated
WBI (42.5 Gy in 16 fractions) or standard WBI (50 Gy in 25 frac-
tions). At 10 years, the rate of local recurrence was 6.2% for the
42.5 Gy arm compared to 6.7% in women receiving standard
fractionation [8]. No difference in Grade 2/3 skin or subcutaneous
toxicity was noted and there was no difference in cosmesis noted.Hypofractionated regional nodal irradiation
With regard to hypofractionation in the post-mastectomy
(PMRT) and/or regional nodal irradiation setting, limited data exist.
While the START A (15% PMRT, 14% regional treatment) and B (8%
PMRT/7% regional treatment) trials incorporated these patients,
comprehensive data on efﬁcacy of hypofractionated RNI for this
subset have not been reported [7]. A recent update of these studies
evaluated the PMRT subset in a limited fashion; for the START A
trial, PMRT patients receiving hypofractionated treatment did not
develop signiﬁcantly more normal tissue effects (based on patient
assessment) with regard to chest wall appearance, chest pain/
swelling, shoulder/arm function, and lymphedema compared with
standard fractionation PMRT. Similar ﬁndings were noted in the
START B PMRT patients when comparing hypofractionation and
standard fractionation. Also, no difference was noted when evalu-
ating chest wall symptoms, shoulder/arm symptoms, and body im-
age in the START A/B trial using the BR23 assessment; however, it
should be noted that the hypofractionated arm of the START A trial
received radiotherapy over 5 weeks rather than 3 weeks [31]. The
initial Marsden study did not include PMRT but did include RNI
in 20% of cases; no difference in lymphedema was noted between
regimens but a subset analysis was not performed [30].
A recent prospective randomized trial from Brussels included
post-mastectomy and regional nodal irradiation patients and
compared a hypofractionated schema (42 Gy in 15 fractions) to
standard fractionation; of the 70 patients in the trial, 40%
(n = 28) received PMRT and 50% (n = 35) received chemotherapy.
Though not stratiﬁed by surgery type, the rate of Grade 3+ acute
skin toxicity was 8% in the hypofractionated arm with no increase
in chronic ﬁbrosis or lymphedema and no change in cardiac func-
tion were noted. A reduction in lung toxicity was noted with the
hypofractionated technique [15]. A study from Greece treated
112 patients with hypofractionated PMRT with 98 receiving che-
motherapy; with a median follow up of 44 months, no cases of
clinical pneumonitis were noted, and 23% developed acute desqua-mation. Clinical outcomes were consistent with previous series
with a 97% local control rate and 84% disease speciﬁc survival at
5 years [32]. A retrospective review from Thailand compared con-
ventional and hypofractionated (2.65 Gy  16–18 fx) PMRT; the
series of 215 patients found no difference in clinical outcomes
and no difference in chest wall appearance, skin ﬁbrosis, brachial
plexopathy, arm edema, pulmonary and cardiac events, or rib frac-
tures with 39 month follow-up [33]. At this time, the data are
promising with regard to hypofractionated PMRT and RNI;
however, more data are needed in the form of prospective trials
examining clinical efﬁcacy as well as toxicity proﬁles.Organs at risk and toxicities associated with RNI
Breast
Both acute and late normal tissue toxicity are important con-
cerns when treating the breast with a hypofractionated regimen.
Based on data from randomized trials as well as prospective data,
with the exception of one fractionation scheme used in the UK
FAST trial [11], there is no worsening of acute or late breast toxic-
ities (appearance or cosmesis) with hypofractionated WBI sched-
ules and in some cases hypofractionation has improved chronic
breast appearance outcomes compared to standard fractionation
[6,7,13,31]. As noted above, the Ontario Oncology Group found
equivalent cosmesis and comparable grade 3 skin toxicity and sub-
cutaneous ﬁbrosis [8]. Similar ﬁndings were noted in the START tri-
als with the 39 Gy arm of the START A arm demonstrating reduced
breast changes and the 40 Gy arm of the START B trial demonstrat-
ing reduced breast changes compared with standard fractionation
[7,31]. The UK FAST trial compared standard fractionation WBI
(50 Gy in 25 fx) to 28.5 or 30 Gy in ﬁve once-weekly fractions of
5.7 or 6.0 Gy, respectively. Patients in the 30 Gy arm had signiﬁ-
cantly worse rates of mild/marked breast changes, as assessed by
blinded observers, and non-blinded physician assessed moderate/
marked adverse effects in the breast compared to patients in the
28.5 Gy arm or patients in the standard WBI arm [11].
In cases where large doses per fraction were utilized (ex. 30 Gy
in 5 fractions), prospective data have shown mixed results when
demonstrating signiﬁcant increases in acute or chronic breast tox-
icity compared with standard fractionation [11,16,24]. Due to in-
creased inhomogeneity and studies demonstrating higher rates of
toxicity with standard fractionation, there is concern about the po-
tential risk of increased breast toxicity in larger breasted women
undergoing hypofractionated schedules. Corbin et al. evaluated
92 large breast patients comparing rates of toxicity with standard
and hypofractionation; hypofractionation (42.6 Gy/16 fx) was
associated with a reduction in focal moist desquamation (26% vs.
11%) which was conﬁrmed by a retrospective study from William
Beaumont Hospital [34,35]. Similarly, Goldsmith et al. evaluated
a subset of 279 patients with large breasts in the UK FAST hypro-
fractionation trial and found that larger breast size was a signiﬁ-
cant risk factor for change in breast appearance [36]. Based on
these data and treatment techniques utilized to deliver RNI
(mono-isocentric, matched 3rd ﬁeld, IMRT), it would be unex-
pected to see an increase in acute and/or late breast toxicities with
the addition of hypofractionated RNI to hypofractionated WBI/
PMRT, at previously tested fractionation schemes, as the RNI ﬁeld
would add minimal dose to the breast; however, future prospec-
tive studies are required to verify these data.
Cardiac
Cardiac toxicity with hypofractionation is a late toxicity and
important to consider. While no cardiac data are available from
the Ontario randomized study, data from START A and B have failed
to demonstrate an increase in ischemic heart disease with the hyp-
ofractionated schedules [7]. These ﬁndings were conﬁrmed by a
42 Hypofx Breast RT Reviewprospective series from Belgium that included a subset of patients
receiving hypofractionated RNI and a retrospective series from
Thailand that included hypofractionated RNI [15,33]. Planning
studies using the linear quadratic model have found that compared
with standard fractionation, hypofractionated schedules may actu-
ally deliver less dose (EQD2) to the heart than standard fraction-
ation based on tangential ﬁelds and an a/b greater than 1.5 [37].
Stokes et al. performed a retrospective analysis of 4,929 women
that had received adjuvant radiation to the breast/chest wall +/
regional nodes. After a median follow-up of 11.7 years they found
that fraction sizes greater than 2 Gy were not associated with in-
creased cardiac events [38]. A prospective study of 300 patients
receiving post-mastectomy radiation on three sequential hypofrac-
tionated protocols found a 5% rate of cardiac toxicity as deﬁned as
a reduction in LVEF of 10% at 5 years (though echocardiogram was
only checked at 2 months on the protocol) [39]. These ﬁndings
have been conﬁrmed on a larger scale; a retrospective study of over
7000 patients found no increase in cardiac toxicity with fractions
greater than 2 Gy with 8 year follow-up [40]. Based on standard
RNI planning and the limited data available, it is unlikely that
the addition of hypofractionated RNI to hypofractionated WBI
would increase the cardiac dose as the RNI ﬁeld is above the supe-
rior cardiac border. The exception would be the inclusion of inter-
nal mammary node irradiation for which there are limited data
with respect to hypofractionation.
Pulmonary
The primary concern with regard to pulmonary toxicity is the
potential for sub-acute pneumonitis and subsequent ﬁbrosis lead-
ing to impaired respiratory function and decreased quality of life.
Randomized data from START A and B and other prospective series
have found the rates of pulmonary ﬁbrosis to be less than 2% for
hypofractionated WBI consistent with data from standard fraction-
ation WBI studies including the recently published MA-20 trial
which found a Grade 2+ pneumonitis rate of 0.2% for WBI alone
[3,7,39]. The addition of RNI does potentially increase the rate of
pneumonitis as more lung is exposed to treatment ﬁelds and was
noted to increase pneumonitis rates in the MA-20 trial compared
to WBI without RNI (1.3% vs. 0.2%, p = 0.01) [3]. While limited pro-
spective data exist regarding hypofractionated RNI and pneumoni-
tis, a small study from Belgium demonstrated a reduced risk of
pneumonitis with hypofractionated RNI compared with standard
fractionation RNI which was conﬁrmed by non-randomized data
from Thailand and Greece [15,32,33]. Further, when examining
dose constraints utilized in current stereotactic approaches for
early stage lung cancer and the subsequent rates of pneumonitis
along with normal tissue guidelines, it is feasible to keep rates of
pneumonitis low when utilizing strict pulmonary constraints with
hypofractionated RNI [41–44]. Moving forward prospective studies
should evaluate the rates of pneumonitis following hypofractionat-
ed RNI and planning studies completed to optimize the amount of
lung in treatment ﬁelds; one potential strategy is to limit the
amount of lung within tangents and supraclavicular ﬁelds.
Lymphedema
RNI increases the potential for breast cancer related lymphe-
dema (BCRL). The addition of RNI to BCS and sentinel lymph node
dissection with WBI has been consistently found to increase the
rates of BCRL from 5–10% to 10–50% and when patients undergo
mastectomy to greater than 60% in some series; recent data from
the MA-20 found that RNI increased BCRL to 7.3% from 4.1% with
WBI alone [3,45–48]. Limited data exist on the radiobiology of
the lymphatic system and the potential for increased toxicities
with hypofractionated schedules. Toxicity review from START A
and B failed to identify higher rates of BCRL in patients undergoing
hypofractionated WBI compared with standard WBI, although asmall subset received RNI [7,31]. Prospective data incorporating
hypofractionated RNI have failed to identify higher rates of BCRL
compared with standard RNI, with small numbers of patients; a
larger retrospective series from Asia also failed to identify higher
rates of arm swelling with hypofractionated RNI incorporated with
hypofractionated PMRT [15,33]. Moving forward, one of the chal-
lenges with assessing for BCRL is utilizing a consistent diagnostic
standard; prospective studies evaluating hypofractionated RNI
must use prospective BCRL assessments starting with a pre-treat-
ment assessment to better quantify the risk of BCRL with hypofrac-
tionated schedules [45].
Brachial plexus
Brachial plexopathy is a major concern with hypofractionated
RNI as toxicity associated with the structure can signiﬁcantly im-
pair arm/shoulder function and quality of life (pain, motor func-
tion, paresthesias) and is related to dose per fraction, total dose,
and volume irradiated. Even assuming low a/b ratios of 1.0–2.0
for the brachial plexus, hypofractionated treatment regimens such
as 40 Gy in 15 fractions would deliver a lower EQD2 to the brachial
plexus than 50 Gy in 25 fractions [49]. With traditional RNI, the
rates of brachial plexopathy are less than 5% while paresthesias
are seen in up to 20% of patients [50–53]. When evaluating hypo-
fractionated WBI, data from START B evaluated a small subset of
patients (n = 82) receiving hypofractionated RNI and found no
cases of brachial plexopathy [7,31]. Similarly, review of START A
identiﬁed only one case of brachial plexopathy in the 41.6 Gy
arm [7,31]. Overall, data from START A and B failed to identify
worsening of arm or shoulder function compared with standard
fractionation treatment [7,31]. A retrospective review examining
hypofractionated PMRT with a subset receiving hypofractionated
RNI found no increase in rates of brachial plexopathy [33].
When looking at larger datasets, a recent review from Delanian
et al. evaluated the risk of plexopathy with hypofractionated RNI
schedules; when using fraction sizes >4 Gy/fx, the rates of plexop-
athy were over 50% in several older series though these studies
used outdated radiation planning and delivery techniques [53–
56]. However, several studies that delivered below 3 Gy/fx, and
limited total dose to less than 45 Gy, found the rates of brachial
plexopathy to be consistently less than 5% consistent with stan-
dard fractionation RNI [57–59]. These ﬁndings were conﬁrmed
by a second large review as well as retrospective PMRT data from
Sweden that found high rates of plexopathy with older techniques
[60,61]. Based on the data above and extrapolating from the head
and neck literature where doses of 60–66 Gy are routinely given,
hypofractionated RNI, at previously tested fractionation schemes,
is promising with respect to shortening treatment duration with-
out signiﬁcantly increasing rates of plexopathy [62,63]; however,
future studies are needed to verify these ﬁndings. One difﬁculty
with prospective trials evaluating hypofractionated RNI will be
the long term follow-up required to document plexopathy as many
cases present beyond 5 years from treatment [64].
Discussion/conclusions
The purpose of this review was to examine the data supporting
hypofractionated RNI based on previously published data on hyp-
ofractionated schedules in breast cancer, toxicities to organs at risk
with hypofractionated RNI and rates of toxicity with standard frac-
tionation RNI. The results of this review demonstrate several key
ﬁndings: (1) based on several randomized trials and many pro-
spective trials, hypofractionated WBI represents a safe and efﬁca-
cious treatment modality, (2) data for hypofractionated RNI are
limited to small subsets of patients from randomized and prospec-
tive trials but is promising though long term efﬁcacy data are lim-
ited, (3) data from hypofractionated breast trials as well as
extrapolation from hypofractionated schedules in other organ sites
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standard fractionation is associated with increased toxicity
compared to WBI alone but current data do not support an in-
creased rate of toxicity with hypofractionated RNI compared with
standard fractionation RNI. Taken together, these data support the
initiation of further clinical trials evaluating hypofractionated RNI
schedules. Demonstrating the safety and efﬁcacy of hypofraction-
ated RNI will allow more women to complete adjuvant radiation
in a shortened treatment duration, potentially decreasing the
underutilization of adjuvant radiation therapy. Further, from a
healthcare economics standpoint, shortened schedules reduces
the costs to the healthcare system and allows for increased avail-
ability of and improved access to expensive radiation therapy
delivery platforms.
Finally, with advances in systemic therapy over the past two
decades and increased utilization of RNI, one concern that must
be evaluated in future studies is the impact of systemic therapy
in concert with RNI (standard and hypofractionated). For example,
when evaluating cardiac toxicity with hypofractionated regimens,
one must take into account the addition of anthracycline based
chemotherapy as well as herceptin. Similarly, pulmonary toxicity
and lymphedema rates must be evaluated in the context of taxane
receipt.
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